NCT00596908 (AIM) is a clinical trial in Upper Extremity Tremor, sponsored by Alseres Pharmaceuticals, Inc.

Who is sponsoring NCT00596908?

NCT00596908 is sponsored by Alseres Pharmaceuticals, Inc.

What condition does NCT00596908 study?

NCT00596908 studies Upper Extremity Tremor.

Is NCT00596908 still recruiting?

NCT00596908 is currently completed. Last updated 28 May 2009.

Last reviewed 2009-05-28 · How we verify

NCT00596908: AIM

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

123I-ALTROPANE® Reference Image Acquisition in Subjects With Diagnostically Uncertain Tremor (AIM)

Completed Last updated 28 May 2009

What this trial tests

trial in Upper Extremity Tremor in 54 participants. Completed in 1 March 2009.

Timeline

1 December 2007

1 March 2009

Quick facts

Lead sponsor	Alseres Pharmaceuticals, Inc
Status	Completed
Study type	OBSERVATIONAL
Enrollment	54
Start date	1 December 2007
Estimated completion	1 March 2009
Sites	7 locations across United States

Conditions studied

Upper Extremity Tremor — all drugs for Upper Extremity Tremor →

Sponsor

Alseres Pharmaceuticals, Inc — full company profile →

Who can join

40 and older, any sex, with Upper Extremity Tremor. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

To obtain a reference set of 123-I ALTROPANE® SPECT images.
Time frame: Image obtained at Visit 2

Sponsor's own description

This study is designed to obtain an imaging training set that will be used to evaluate images in future trials. Currently, no radiopharmaceutical diagnostic imaging agent has been approved by the FDA in the U.S. for use in diagnosing Parkinson disease and related Parkinsonian syndromes. The diagnosis of Parkinsonian syndromes in the U.S. is based on clinical criteria only. The goal is to demonstrate that 123I-ALTROPANE® paired with SPECT imaging permits a more accurate early diagnosis of Parkinson disease than a clinical diagnosis by a general neurologist.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00596908 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Alseres Pharmaceuticals, Inc
Last refreshed: 28 May 2009

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00596908.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing